Loading clinical trials...
Loading clinical trials...
Open Label Maximal Use Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitis
Conditions
Interventions
Tapinarof cream, 1%
Locations
10
United States
Dermavant Investigative Site
Thousand Oaks, California, United States
Dermavant Investigative Site
Centennial, Colorado, United States
Dermavant Investigative Site
Coral Gables, Florida, United States
Dermavant Investigative Site
Hialeah, Florida, United States
Dermavant Investigative Site
Miami Lakes, Florida, United States
Dermavant Investigative Site
Chicago, Illinois, United States
Start Date
November 15, 2021
Primary Completion Date
August 24, 2022
Completion Date
August 24, 2022
Last Updated
September 5, 2025
NCT07262983
NCT06389136
NCT06342713
NCT07223697
NCT07290803
NCT07265479
Lead Sponsor
Organon and Co
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions